Tom Blickman, Katie Sandwell, Dania Putri, Xabier Arana, Tom Decorte, Vibeke Asmussen Frank, Dirk J. Korf, Ingo Ilja Michels, Maj Nygaard-Christensen, Tim Pfeiffer-Gerschel, Heino Stöver, Bernd Werse, Frank Zobel
20 March 2019
In order to better understand the situation around, and possibilities for, local and regional cannabis regulation, a series of six country reports were developed. The country reports provide detailed information about the state of cannabis policy, and the possibilities for change, within each country. This Report summarises some of the key findings from the research and explores opportunities, obstacles, and strategies for cannabis regulation at the municipal and regional level.
Local and regional authorities across Europe are confronted with the negative consequences of a persisting illicit cannabis market. Increasingly, local and regional authorities, non-governmental pressure groups and grassroots movements are advocating a regulation of the recreational cannabis market.
The mayor of Bogota has recently proposed a pilot scheme with crack cocaine addicts to explore the substitution of crack made of cocaine base paste (or bazuco as it is called in Colombia) by marijuana. The substitution treatment plan will include 15 problematic users from the marginalized Bronx area who are already receiving health assistance of the CAMAD operating in that sector of the city. The treatment will last approximately eight months, after which the results will be evaluated.
Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications.
The Washington Office on Latin America (WOLA) and the Transnational Institute (TNI) invited a group of 20 experts for a round-table discussion at the WOLA office in Washington DC . The main question on the table: can the concept of “harm reduction” be applied to supply-oriented challenges to better address the harms associated with illicit drug production and distribution, but also minimize the harms that stem from drug control itself?
Philippe Lucas, Amanda Reiman, Mitch Earleywine, Stephanie K. McGowan, Megan Oleson, Michael P. Coward, Brian Thomas
19 November 2012
This article examines the subjective impact of medical cannabis on the use of both licit and illicit substances via self-report from 404 medical cannabis patients recruited from four dispensaries in British Columbia, Canada. The aim of this study is to examine a phenomenon called substitution effect, in which the use of one product or substance is influenced by the use or availability of another.
A report published in March 2007 by the Canadian HIV/AIDS Legal Network and the Open Society Institute Public Health Program, strongly criticises the INCB. It accuses the Board of becoming 'an obstacle to effective programs to prevent and treat HIV and chemical dependence'. “Nearly one in three HIV infections outside Africa is among people who inject drugs. The International Narcotics Control Board could and should be playing a key role in stopping this injection-driven HIV epidemic — but it’s not,” said Joanne Csete, Executive Director of the Canadian HIV/AIDS Legal Network and co-author of the report.
A top Russian diplomat, Yuri V. Fedotov, has emerged as the front-runner in the race to become the Executive Director of the UN Office on Drugs and Crime (UNODC) – the world's new drug czar, according to Colum Lynch, a longtime Washington Post correspondent who reports on the United Nations for Turtle Bay.
Critics of the international drug control regime contend that supply-oriented policy interventions are not just ineffective, but they also produce unintended adverse consequences. Research suggests their claims have merit. Lasting local reductions in opium production are possible, albeit rare; but, unless global demand shrinks, production will shift elsewhere, with little or no effect on the aggregate supply of heroin and, potentially, at some expense to exiting and newly emerging suppliers.
In Australia a vicious debate on cannabis policy started when Alex Wodak, the head of the Sydney drug and alcohol clinic at St Vincent's Hospital, suggested that marijuana be regulated like alcohol or tobacco. He proposed to sell cannabis legally in post offices in packets that warn against its effects.
The widespread legal, social and political ramifications of the HIV/AIDS epidemic make it necessary to review and reform a broad range of laws. Some countries have adopted national HIV/AIDS laws, but these laws often ignore crucial policy issues, as well as human rights abuses that perpetuate the HIV epidemic. This is particularly true with respect to illegal drug use.
An interesting essay discussing the case for decriminalization of cannabis use appeared in the March 2008 issue of Current Opinion in Psychiatry. The Dutch psychiatrist Wim van den Brink of the Amsterdam Institute for Addiction Research carefully weighs the currently available evidence regarding advantages and risks of such a policy change.
The issue of harm reduction continues to be controversial during the negotiations in Vienna for the Political Declaration that has to be adopted in March 2009 at the High Level Segment of the Commission on Narcotic Drugs (CND). There is severe pressure on delegates to drop their insistence on incorporating the language and principles of harm reduction in the political declaration, or to accept some watered down version.
The opening in September 2012 of the first centre for drug addicts in Bogota is a welcome first step towards more humane and effective drug policies in Colombia’s capital city, but to be effective needs to be integrated into proper overall drugs strategy.
As a participant at last week’s 19th International HIV/AIDS Conference, I was reminded of President Fernando Henrique Cardoso’s and UNDP Administrator Helen Clark’s call to arms earlier in July that there is a new prescription for the AIDS response: ‘courage is needed’.
James Shearer, John Sherman, Alex Wodak, Ingrid van Beek
31 May 2002
The illicit use of amphetamines continues to be a growing problem in many countries around the world, yet treatment responses remain in need of further development. This is particularly true with regards to pharmacotherapy for amphetamine dependence. In this Harm Reduction Digest four authors who bring together considerable research and clinical experience in this area describe the nature of amphetamine-related problems and consider the role of amphetamine agonists in substitution therapy for amphetamine dependence.
During IHRA's 19th international conference this month the Hungarian Civil Liberties Union (HCLU) recorded a film which poses a series of questions to Antonio Maria Costa, Executive Director of the UNODC, from a range of user representatives, harm reduction experts and drug policy advocates.
The upcoming United Nations General Assembly Special Session on Drugs (UNGASS) in 2016 is an unprecedented opportunity to review and re-direct national drug control policies and the future of the global drug control regime. As diplomats sit down to rethink international and domestic drug policy, they would do well to recall the mandate of the United Nations, not least to ensure security, human rights and development.
In 2004, a team comprised of researchers and service providers launched the Safer Crack Use, Outreach, Research and Education (SCORE) project in the Downtown Eastside of Vancouver, British Columbia, Canada. The project was aimed at developing a better understanding of the harms associated with crack cocaine smoking and determining the feasibility of introducing specific harm reduction strategies.